Estimating the Factor VIII-Equivalent Activity of Emicizumab Using Global Assays of Haemostasis.

ABSTRACT:

Background

Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII-equivalent activity (FVIIIeq) of emicizumab remains unknown.

Objectives

To estimate FVIIIeq of emicizumab using global assays of haemostasis.

Patients/methods

We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one-stage assay (OSA). Using principal components (P

SUBMITTER: Kraemmer D 

PROVIDER: S-EPMC12462556 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature